Core Viewpoint - The company, 瑞迈特, is experiencing a performance rebound due to the recovery of its North American business, with significant growth in revenue and net profit reported for the first three quarters of 2025 [2][3]. Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 808 million yuan, a year-on-year increase of 34.24% [2]. - The net profit attributable to shareholders reached 180 million yuan, reflecting a year-on-year growth of 43.87% [2]. - The non-recurring net profit saw a year-on-year increase of 63.41% [2]. - The gross margin in the domestic market improved, increasing by 14.57% year-on-year and 11.63% quarter-on-quarter [2]. Market Recovery - The company's revenue from the U.S. market grew by 63.46% year-on-year and 52.28% quarter-on-quarter [2]. - The U.S. market is identified as the company's primary market, with significant recovery expected following a period of inventory destocking [2][3]. Product Development - The company launched the G3X model non-noise cotton respirator in the U.S., which has received FDA approval and completed medical reimbursement code registration, filling a product gap in the high-end market [3]. - Revenue from the U.S. region for the first three quarters of this year increased by 133.85% [3]. Strategic Focus - The company aims to enhance its brand presence and marketing efforts domestically, recognizing the need to align its brand status with its technological and product capabilities [5]. - The company plans to establish a localized presence in Europe and increase its market share in the region, which is seen as a significant growth opportunity [5]. Future Outlook - The company is transitioning from being merely a device manufacturer to creating a comprehensive respiratory disease management ecosystem, integrating hardware, software, and services [6]. - The domestic market is expected to continue growing, with the company anticipating stable market share and potential growth through enhanced services and high-end product offerings [7].

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2][3]. - The company is a leading domestic manufacturer of non-invasive ventilators and masks, being the first domestic company to receive FDA certification for non-invasive ventilators, with products sold in over 100 countries [2][3]. R&D and Patents - As of June 30, 2025, the company holds 666 valid domestic patents, including 116 invention patents, 404 utility model patents, and 146 design patents. It also has 266 overseas patents, including 45 in the U.S. and 38 in Europe [3]. Financial Performance Revenue - For the first three quarters of 2025, the company reported a revenue of 808 million CNY, a year-on-year increase of 34.24%. The revenue for Q3 alone was 264 million CNY, up 20.22% year-on-year [4]. - Domestic revenue for the first three quarters was 251 million CNY, a growth of 5.51%, while overseas revenue reached 558 million CNY, marking a significant increase of 52.96% [5]. Product Segmentation - Revenue from home ventilators accounted for 521 million CNY (64.51% of total revenue), with a year-on-year growth of 39.07%. Consumables generated 262 million CNY (32.38% of total revenue), growing by 27.26% [6]. Gross Margin - The gross margin for the first three quarters of 2025 was 52.37%, an increase of 1.17% compared to the previous year. The gross margin for Q3 was 52.79%, up 2.47% year-on-year [9]. Market Insights - In Q3, overseas revenue was 205 million CNY, with a year-on-year growth of 40.41% and a quarter-on-quarter growth of 11.92%. The U.S. market contributed significantly, with a year-on-year increase of 63.46% [7]. - The company holds a 8.9% market share in Europe, ranking third, with plans to expand its cloud platform through the integration of over a thousand distributors [9]. Future Outlook - The company is transitioning from an online distribution model to a direct sales model, expecting to see performance improvements starting in Q4 2025. New product registrations, including portable oxygen machines, are anticipated to contribute to domestic revenue growth [10]. - The company has received product registration in Canada, with an estimated annual market potential of 150,000 units [10]. Strategic Initiatives - The company is actively pursuing mergers and acquisitions, focusing on high-potential companies in precision motor and medical technology sectors to enhance its core competitiveness [10]. - It has achieved significant localization in its supply chain, ensuring domestic production of core components, which enhances cost efficiency and technical independence [10].

Core Viewpoint - 瑞迈特 reported strong financial performance for the first three quarters of 2025, with significant year-on-year growth in both revenue and net profit [1] Financial Performance - The company achieved a total revenue of 808 million yuan for the first three quarters, representing a year-on-year increase of 34.24% [1] - The net profit attributable to shareholders for the same period was approximately 180 million yuan, reflecting a year-on-year growth of 43.87% [1] - In the third quarter alone, 瑞迈特 generated revenue of 264 million yuan, which is a 20.22% increase compared to the previous year [1] - The net profit for the third quarter was about 48.66 million yuan, marking a substantial year-on-year increase of 48.61% [1]

Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong financial performance and growth potential [1] - The company is implementing a multi-model product sales strategy for its online self-operated platform and differentiating its offline product offerings to enhance market presence [1] - The completion of the European cloud platform and the integration of existing and new agents is expected to facilitate the company's transition from non-mainstream to mainstream medical insurance markets in Europe [2] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 808 million yuan, a year-on-year increase of 34.24% [1] - The net profit attributable to shareholders reached 180 million yuan, reflecting a year-on-year growth of 43.87% [1] - The net profit excluding non-recurring gains and losses was 140 million yuan, up 63.41% year-on-year [1] - In the third quarter alone, the company reported operating revenue of 264 million yuan, a 20.22% increase compared to the same period last year [1] - The net profit attributable to shareholders for the third quarter was 48.66 million yuan, marking a 48.61% year-on-year growth [1] - The net profit excluding non-recurring gains and losses for the third quarter was 40.39 million yuan, showing a substantial increase of 112.64% year-on-year [1] Strategic Developments - The company is focusing on a stable transition to online channels, with an overall positive operational trend in domestic business [1] - The strategy includes synchronizing the sales of multiple product models online while differentiating offline product offerings to complement the online strategy [1] - The establishment of the European cloud platform is a key milestone for the company, providing a solid foundation for sustainable development in the European market [2]

Core Insights - The company reported a revenue of 264,378,729.58 yuan for the third quarter of 2025, representing a year-on-year growth of 20.22% [1] - The net profit attributable to shareholders of the listed company was 48,663,031.16 yuan, showing a significant year-on-year increase of 48.61% [1] Financial Performance - Revenue for Q3 2025: 264,378,729.58 yuan, up 20.22% year-on-year [1] - Net profit for Q3 2025: 48,663,031.16 yuan, up 48.61% year-on-year [1]

Core Viewpoint - Beijing Ruimait Medical Technology Co., Ltd. is experiencing a decline in stock price, with a drop of 3.60% on October 27, resulting in a market capitalization of 7.638 billion yuan [1] Company Overview - The company specializes in manufacturing medical devices and consumables in the field of respiratory health, including various types of sleep apnea machines and monitoring devices [2][7] - Established on July 27, 2001, and listed on November 1, 2022, the company provides comprehensive treatment solutions for patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [7] Financial Performance - For the first half of 2025, the company achieved a revenue of 544 million yuan, representing a year-on-year growth of 42.30%, and a net profit attributable to shareholders of 131 million yuan, also up by 42.19% [8] - As of June 30, 2025, the company reported that 64.19% of its revenue came from home respiratory therapy products, 32.67% from consumables, and 3.05% from medical products [7] Market Position and Shareholder Information - The company has a significant overseas revenue contribution, accounting for 64.21% of total revenue, benefiting from the depreciation of the RMB [3] - As of June 30, 2025, the number of shareholders decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [8] Investment and Partnerships - The company holds a 14.28% stake in Deda Xingshu, a leading domestic provider of precision motors and solutions, which focuses on applications in AI, robotics, and medical fields [3]

Core Insights - The company reported a revenue of 808 million yuan for the first three quarters of 2025, representing a year-on-year growth of 34.24% [1] - The net profit attributable to shareholders reached 180 million yuan, showing a year-on-year increase of 43.87% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 140 million yuan, reflecting a year-on-year growth of 63.41% [1] - The basic earnings per share stood at 2.0252 yuan [1]

Group 1 - The core point of the article is that Ruimait (SZ 301367) held its 16th meeting of the third board session on October 27, 2025, to review the full report for the third quarter of 2025 [1] - For the first half of 2025, Ruimait's revenue composition was as follows: home ventilators accounted for 64.19%, consumables 32.67%, medical products 3.05%, and other businesses 0.1% [1] - As of the time of reporting, Ruimait's market capitalization was 7.6 billion yuan [1] Group 2 - The article also mentions a significant development regarding the private shipping king taking over Shanshan Group, indicating potential complexities in the restructuring process [1]

出席本次业绩说明会的人员拟定为：公司董事长兼总经理庄志先生、独立董事厉洋 先生、副总经理兼董事会秘书杜祎程先生、副总经理兼财务总监暴楠先生。具体以当天 实际参加会议人员为准。 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向广大投资 者公开征集问题，投资者可提前登录"互动易"平台（http://irm.cninfo.com.cn）"云访 谈"栏目进入公司本次业绩说明会页面进行提问，或扫描下方二维码进入问题征集专题 页面。公司将在本次业绩说明会上，对投资者普遍关注的问题进行回答。在业绩说明会 期间，投资者仍可登陆活动界面进行互动提问。 1 欢迎广大投资者积极参与本次网上业绩说明会。 证券代码：301367 证券简称：瑞迈特 公告编号：2025-063 北京瑞迈特医疗科技股份有限公司 关于举行2025年第三季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京瑞迈特医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日发 布了《2025 年第三季度报告》，并披露于中国证监会指定的创业板信息披露网站巨潮 ...

一、董事会会议召开情况 北京瑞迈特医疗科技股份有限公司（以下简称"公司"）第三届董事会第十 六次会议于 2025 年 10 月 27 日在公司会议室以现场结合通讯的方式召开，会议 通知已于 2025 年 10 月 20 日以书面、电子邮件方式发出并送达全体董事。本次 会议由公司董事长庄志先生召集并主持。本次会议应出席的董事 9 人，实际出席 的董事 9 人，其中董事陈蓓女士、周明钊先生、崔文立先生、TAN CHING（谈 庆）先生、厉洋先生、库逸轩先生、孙培睿先生以通讯方式参加会议。公司高级 管理人员列席了本次会议。本次会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《北京瑞迈特医疗科技股份有限公司章程》的规定。 二、董事会会议审议情况 经全体与会董事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于公司 2025 年第三季度报告全文的议案》； 经审议，董事会认为公司《2025 年第三季度报告》的编制和审核程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 2025 年第三季度的经营成果和财务状况，不存在任何虚假记载、误导性陈述或 重大遗漏。 证券代码：301 ...